Johnson & Johnson (JNJ)
Johnson & Johnson slides as soft sales guidance casts shadow
Johnson & Johnson shares faced pressure on Wednesday as soft sales guidance for the coming year cast a shadow over expectation-beating fourth-quarter profit. Adjusted net earnings of US$4.95 billion were down 11.1% year on year in the fourth quarter, J&J reported, but ahead of consensus expectations for US$4.88 billion.
Compared to Estimates, Johnson & Johnson (JNJ) Q4 Earnings: A Look at Key Metrics
The headline numbers for Johnson & Johnson (JNJ) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Trump Tariffs Take Shape, Stargate AI Project Ramps Up, JNJ & PG Beat
Kevin Green joins Morning Movers to look at how President Trump's tariffs plan could impact several areas of the market, specifically currencies and copper. Then, the focus shifts to Trump's ambitious A.I.
J&J Tops Q4 Adjusted Earnings Estimates, But 2025 Sales Outlook Falls Short
Johnson & Johnson (JNJ) posted its fourth-quarter earnings report Wednesday morning, with adjusted profits beating expectations while the company's sales projections for the coming fiscal year fell short.
Johnson & Johnson Tops Q4 EPS Forecasts
Pharmaceuticals and medical devices manufacturer Johnson & Johnson (JNJ 0.76%) reported fourth-quarter 2024 results on Wednesday, Jan. 22, that topped analyst consensus estimates. Revenue of $22.5 billion came in just ahead of forecasts for $22.4 billion while adjusted earnings per share (EPS) of $2.04 also surpassed the $1.99 estimate.
Johnson & Johnson (JNJ) Q4 Earnings and Revenues Top Estimates
Johnson & Johnson (JNJ) came out with quarterly earnings of $2.04 per share, beating the Zacks Consensus Estimate of $2 per share. This compares to earnings of $2.29 per share a year ago.
J&J CFO Joe Wolk: Anticipating 3% operational growth in 2025 despite 'significant' headwinds
Johnson & Johnson executive vice president and CFO Joseph Wolk joins 'Squawk Box' to discuss the company's quarterly earnings results, slowdown in China, health care landscape in 2025, impact of the second Trump administration, and more.
J&J's stock surrenders early gains as weak sales guidance offsets earnings beat
Medtech and drug company's 2025 sales guidance is below consensus
J&J beats quarterly sales and profit estimates on cancer drug sales
Johnson & Johnson , fresh off a $14.6 billion deal to buy neurological drugmaker Intra-Cellular , reported fourth-quarter sales and profit above Wall Street estimates on Wednesday, driven by strong sales of its cancer treatments.
Johnson & Johnson Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Johnson & Johnson JNJ will release earnings results for its fourth quarter, before the opening bell on Wednesday, Jan. 22, 2025.
Q4 Earnings: 3 Consumer Staples Titans on Deck
Among the bunch of companies expected to report in the coming days include a few consumer staples titans such as Procter & Gamble, Johnson & Johnson, and Kimberly-Clark.
Johnson & Johnson Q4 Earnings Loom As FDA Approves Depression Drug: Will Long-Term Weakness Reverse?
Johnson & Johnson JNJ will be reporting its fourth-quarter earnings on Wednesday. Wall Street expects $2 in EPS and $22.44 billion in revenues as the company reports before market hours.
